Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019
To access the live conference call, please dial 866-922-5184 (domestic)
or 409-937-8950 (international), and refer to conference ID 8294495. A
webcast of the call will also be available under “Events &
Presentations” in the Investors section of the
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic
alliances for development programs with
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005753/en/
Source:
Moderna Contacts:
Investors:
Lorence Kim
Chief
Financial Officer
617-209-5849
Lorence.kim@modernatx.com
Media:
Jason Glashow
Head, Corporate Communications
617-674-5648
Jason.glashow@modernatx.com